OvaRex (oregovomab) / Hikma, Orient Europharma, Specialised Therap, Shenzhen Hepalink, CanariaBio 
Welcome,         Profile    Billing    Logout  

6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
OvaRex (oregovomab) / CanariaBio
FLORA-4, NCT04498117 / 2020-002270-26: Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Active, not recruiting
3
615
Europe, Canada, US, RoW
Oregovomab, MAb-B43.13, Paclitaxel, Taxol, Carboplatin, Paraplatin, Placebo
CanariaBio Inc., Gynecologic Oncology Group, Iqvia Pty Ltd
Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms
09/25
08/27
QPT-ORE-004, NCT05335993: A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.

Active, not recruiting
2
10
US
Oregovomab, MAb-B43.13, Monoclonal antibody B43.13, Niraparib, Zejula
CanariaBio Inc., Veristat, LLC
Recurrent Ovarian Cancer, Recurrent Epithelial Cancer of Ovary, Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Peritoneal Cancer, Recurrent Carcinoma of Ovary, Adenocarcinoma of Ovary
03/24
12/24
OPERA, NCT05407584: Oregovomab and PLD in PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment

Recruiting
2
56
RoW
Orevogomab+PLD, Orevogomab+Paclitaxel
Yonsei University, CanariaBio Inc.
PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment
05/24
11/24
QPT-ORE-006, NCT05605535: Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer

Recruiting
2
88
RoW
Oregovomab, MAb-B43.13, Paclitaxel, Taxol, Carboplatin, Paraplatin, Placebo
CanariaBio Inc., Raptim Research Pvt. Ltd
Ovarian Neoplasm Epithelial, Ovarian Cancer, Fallopian Tube Neoplasms, Peritoneal Carcinoma, Ovarian Serous Adenocarcinoma
09/24
05/26
NCT04938583: Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer

Recruiting
1b/2
54
RoW
Oregovomab, MAb-B43.13, Bevacizumab, Avastin, Paclitaxel, Taxol, Paxcel, Padexol, Carboplatin, Neoplatin
CanariaBio Inc., Korean Cancer Study Group
Ovarian Cancer by FIGO Stage, Ovarian Cancer Stage III, Ovarian Cancer Stage IV
04/24
12/25
ORION-02, NCT04620954: Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin

Recruiting
1/2
31
RoW
Oregovomab, Nivolumab, Chemotherapy
National Cancer Centre, Singapore, OncoQuest Pharma USA Inc., Bristol-Myers Squibb
Epithelial Ovarian Cancer
07/22
07/22

Download Options